Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(14):1049-1050; doi:10.1093/jnci/94.14.1049
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 14, 1049-1050, July 17, 2002
© 2002 Oxford University Press

NEWS

Researchers Push for Sharing of Trial Results with Participants

Linda Wang

The first 10% of the full text of this article appears below.

In 1998, the National Surgical Adjuvant Breast and Bowel Project initiated a massive undertaking to inform more than 13,000 study participants of preliminary results from the Breast Cancer Prevention Trial. The study found that women taking tamoxifen experienced almost a 50% decrease in breast cancer risk compared with women taking a placebo.

The NSABP ended the trial early and sent results to each woman who participated in the trial. In addition, investigators made numerous phone calls to make sure each woman had received the information. "The NSABP had never taken on an effort of this magnitude," said Larry Wickerham, M.D., NSABP’s vice-chairman. Following notification, many of the women in the placebo group began taking tamoxifen.

This situation was unique in that the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?